The aera of personalized treatment, the introduction of targeted therapy was most frequent at adenocarcinoma, especially at young patients (ALK inhibitors), while in older women, the possibility of EGFR inhibition resulted in visible improvement [32]. This evidence concerns the gene EGFR and adenocarcinoma.